Company says it is on track to double capacity in South Africa by year end.
Clinical trials company Synexus formally opened two new dedicated research centers in Pretoria, South Africa. They will complement Synexus’ existing site in South Africa, which has a 36-bed Phase I and IIa trial unit.
U.K.-based Synexus is a multinational company dedicated to the recruitment and running of clinical trials. In October 2008 the company announced plans to double its clinical trials capacity in South Africa and claims that it is on track to reach that goal by the end of 2009.
Ian Smith, M.D., Synexus’ medical director, states that the company’s operations in South Africa have shown “impressive” growth year-on-year. “The combination of the large patient population and the highly skilled medical community make it a sought after destination for pharmaceutical and biotech companies who are finding patient recruitment increasingly difficult. We currently have four major trials under way here, all part of wider international studies, as well as more than 30 Phase I to Phase III trials.”